Phase I clinical trial of nintedanib plus paclitaxel in early HER-2-negative breast cancer (CNIO-BR-01-2010/GEICAM-2010-10 study).
Br J Cancer
; 111(6): 1060-4, 2014 Sep 09.
Article
em En
| MEDLINE
| ID: mdl-25058346
ABSTRACT
INTRODUCTION:
Previous small-molecule antiangiogenics have compromised chemotherapy dose intensity in breast cancer. We present a phase I trial of a novel selective agent, nintedanib, plus standard chemotherapy in early breast cancer.METHODS:
Her-2-negative breast cancer patients with tumours larger than 2 cm were eligible for dose-escalation trial (classic 3+3 method).RESULTS:
The recommended phase II dose (RP2D) was 150 mg BID of nintedanib combined with standard dose of weekly paclitaxel followed by adriamycin plus cyclophosphamide. The dose-limiting toxicity was transaminase elevation. At the RP2D, the dose intensity was â¼100%. The pathologic complete response was 50%.CONCLUSIONS:
The combination allows the delivery of full-dose intensity, while efficacy seems promising.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Mama
/
Protocolos de Quimioterapia Combinada Antineoplásica
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article